• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在有组织的宫颈癌筛查计划实施之前,认证发育异常单位针对宫颈、外阴和阴道发育异常及其他疾病患者的标准化程序。

Standardized Procedures for Patients with Dysplasia and Other Diseases of the Cervix, Vulva, and Vagina at a Certified Dysplasia Unit Prior to the Introduction of the Organized Cervical Cancer Screening Program.

作者信息

Schulmeyer Carla E, Koch Martin C, Dietl Anna K, Stuebs Frederik A, Behrens Annika, Renner Simone K, Mehlhorn Grit, Geppert Carol C, Hartmann Arndt, Beckmann Matthias W, Gass Paul

机构信息

Frauenklinik des Universitätsklinikums Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Comprehensive Cancer Center Erlangen/Europäische Metropolregion Nürnberg (CCC ER-EMN), Erlangen, Germany.

Klinik für Gynäkologie und Geburtshilfe, ANregiomed Klinikum Ansbach, Ansbach, Germany.

出版信息

Geburtshilfe Frauenheilkd. 2023 Aug 15;83(8):1031-1042. doi: 10.1055/a-1934-1686. eCollection 2023 Aug.

DOI:10.1055/a-1934-1686
PMID:37588259
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10427204/
Abstract

Gynecologic dysplasia units and dysplasia consultations are obliged to offer diagnosis and treatment in accordance with the guidelines. The organization of the consultation process, management of patient appointments, diagnosis, and treatment algorithms are heterogeneous. The legislation arising from the new Federal Joint Committee decision, dated 22 November 2018, concerning the organized cervical cancer screening program has been in force since 1 January 2020. In this article we provide an overview of the existing structures and interdisciplinary cooperation of specialized dysplasia units incorporated in certified gynecologic cancer center. We carried out a retrospective database search of data collected prospectively from 1 July 2014 to 31 December 2019 at the dysplasia unit at the Department of Gynecology and Obstetrics, Erlangen University Hospital, which was the first dysplasia unit to be certified in 2014. A total of 5594 patients presented at the unit, and 16061 colposcopic, vulvoscopic, and anoscopic examinations were performed. Approximately 4100 examinations of the cervix, vagina, vulva, and anus are carried out each year, 1600 of these were exclusively cervix colposcopies. A total of 12197 cytology results were assessed, as well as 4850 histology results, and 8193 high-risk HPV tests. The quality indicators required by the dysplasia unit for annual recertification were met each year. Certified dysplasia units and consultations form the central component in the algorithm for further investigating abnormal screening results; but they are also the first point of contact for a large number of patients with acute or chronic complaints in the genital region.

摘要

妇科发育异常科室及发育异常会诊必须按照指南提供诊断和治疗。会诊流程的组织、患者预约管理、诊断及治疗算法各不相同。2018年11月22日新的联邦联合委员会关于有组织的宫颈癌筛查项目的决定所产生的法规自2020年1月1日起生效。在本文中,我们概述了纳入认证妇科癌症中心的专业发育异常科室的现有结构和跨学科合作情况。我们对2014年7月1日至2019年12月31日在埃尔朗根大学医院妇产科发育异常科室前瞻性收集的数据进行了回顾性数据库搜索,该科室是2014年首个获得认证的发育异常科室。共有5594名患者到该科室就诊,进行了16061次阴道镜、外阴镜和肛门镜检查。每年大约进行4100次宫颈、阴道、外阴和肛门检查,其中1600次仅为宫颈阴道镜检查。共评估了12197份细胞学结果、4850份组织学结果以及8193次高危型人乳头瘤病毒检测。该发育异常科室每年都达到了年度重新认证所需的质量指标。认证的发育异常科室及会诊是进一步调查异常筛查结果算法中的核心组成部分;但它们也是大量患有急性或慢性生殖器区域疾病患者的首个接触点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/5d652f1625cf/10-1055-a-1934-1686_19355945.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/ff82eae6badc/10-1055-a-1934-1686_19515274.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/a56a2cc93bb8/10-1055-a-1934-1686_19515541.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/333332da93a6/10-1055-a-1934-1686_19515542.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/06d5d0892277/10-1055-a-1934-1686_19515543.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/c8367d9507fd/10-1055-a-1934-1686_19515544.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/d7e9ad7aea75/10-1055-a-1934-1686_19515545.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/37147f21fced/10-1055-a-1934-1686_19515546.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/d5ce3f3eb435/10-1055-a-1934-1686_19515547.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/4263e0560991/10-1055-a-1934-1686_19515548.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/77526a922e5a/10-1055-a-1934-1686_19515549.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/47a80ec7f4f8/10-1055-a-1934-1686_19355916.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/62be4bbf608f/10-1055-a-1934-1686_19355917.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/00110c92bcb3/10-1055-a-1934-1686_19355918.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/57f9487d1617/10-1055-a-1934-1686_19355919.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/a64c9238cf83/10-1055-a-1934-1686_19355920.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/ccf0422b262d/10-1055-a-1934-1686_19355941.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/391d4413c568/10-1055-a-1934-1686_19355942.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/03d99247b5b2/10-1055-a-1934-1686_19355943.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/2d2c023148b5/10-1055-a-1934-1686_19355944.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/5d652f1625cf/10-1055-a-1934-1686_19355945.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/ff82eae6badc/10-1055-a-1934-1686_19515274.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/a56a2cc93bb8/10-1055-a-1934-1686_19515541.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/333332da93a6/10-1055-a-1934-1686_19515542.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/06d5d0892277/10-1055-a-1934-1686_19515543.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/c8367d9507fd/10-1055-a-1934-1686_19515544.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/d7e9ad7aea75/10-1055-a-1934-1686_19515545.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/37147f21fced/10-1055-a-1934-1686_19515546.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/d5ce3f3eb435/10-1055-a-1934-1686_19515547.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/4263e0560991/10-1055-a-1934-1686_19515548.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/77526a922e5a/10-1055-a-1934-1686_19515549.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/47a80ec7f4f8/10-1055-a-1934-1686_19355916.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/62be4bbf608f/10-1055-a-1934-1686_19355917.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/00110c92bcb3/10-1055-a-1934-1686_19355918.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/57f9487d1617/10-1055-a-1934-1686_19355919.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/a64c9238cf83/10-1055-a-1934-1686_19355920.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/ccf0422b262d/10-1055-a-1934-1686_19355941.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/391d4413c568/10-1055-a-1934-1686_19355942.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/03d99247b5b2/10-1055-a-1934-1686_19355943.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/2d2c023148b5/10-1055-a-1934-1686_19355944.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a36/10427204/5d652f1625cf/10-1055-a-1934-1686_19355945.jpg

相似文献

1
Standardized Procedures for Patients with Dysplasia and Other Diseases of the Cervix, Vulva, and Vagina at a Certified Dysplasia Unit Prior to the Introduction of the Organized Cervical Cancer Screening Program.在有组织的宫颈癌筛查计划实施之前,认证发育异常单位针对宫颈、外阴和阴道发育异常及其他疾病患者的标准化程序。
Geburtshilfe Frauenheilkd. 2023 Aug 15;83(8):1031-1042. doi: 10.1055/a-1934-1686. eCollection 2023 Aug.
2
Anal dysplasia screening: an evidence-based analysis.肛门发育异常筛查:基于证据的分析。
Ont Health Technol Assess Ser. 2007;7(4):1-43. Epub 2007 Jun 1.
3
Correlation between referral cytology and in-house colposcopy-guided cytology for detecting early cervical neoplasia.转诊细胞学与阴道镜引导下细胞学检查在早期宫颈癌检测中的相关性。
Arch Gynecol Obstet. 2020 Jan;301(1):263-271. doi: 10.1007/s00404-019-05389-1. Epub 2019 Dec 6.
4
A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study.一项横断面研究:高级别宫颈、阴道和外阴发育不良或癌症女性中肛门发育不良的患病率:PANDA 研究。
Cancer Epidemiol Biomarkers Prev. 2022 Dec 5;31(12):2185-2191. doi: 10.1158/1055-9965.EPI-22-0548.
5
Repeated Positive Cervical HPV Testing and Absent or Minor Cytology Abnormality at Pap Smear. What is the Next Step?重复的宫颈 HPV 检测阳性且巴氏涂片未见或仅有轻微细胞学异常。下一步该怎么做?
Asian Pac J Cancer Prev. 2021 Jun 1;22(6):1907-1912. doi: 10.31557/APJCP.2021.22.6.1907.
6
Colposcopy, cervicography, speculoscopy and endoscopy. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.阴道镜检查、宫颈造影、直接视诊镜检查和内窥镜检查。国际细胞学会工作组总结。迈向21世纪的诊断细胞学:一次国际专家会议及教程。
Acta Cytol. 1998 Jan-Feb;42(1):33-49. doi: 10.1159/000331533.
7
Prevalence of anal dysplasia and HPV genotypes in gynecology patients: The ANGY cross-sectional prospective clinical study protocol.妇科患者肛门发育不良和 HPV 基因型的流行情况:ANGY 横断面前瞻性临床研究方案。
PLoS One. 2022 Oct 21;17(10):e0276438. doi: 10.1371/journal.pone.0276438. eCollection 2022.
8
The clinical value of digene hybrid capture HPV DNA testing in a referral-based population with abnormal pap smears.在基于转诊的巴氏涂片异常人群中,Digene杂交捕获HPV DNA检测的临床价值。
Eur J Gynaecol Oncol. 1998;19(3):203-8.
9
Quality assurance using quality indicators for prevention and early detection of cervical cancer in certified gynaecological dysplasia units and consultancies.使用质量指标进行宫颈癌的预防和早期发现的质量保证:在认证的妇科发育不良单位和咨询机构中。
Arch Gynecol Obstet. 2024 Oct;310(4):2191-2202. doi: 10.1007/s00404-024-07694-w. Epub 2024 Aug 29.
10
Concordance of HPV, conventional smear, colposcopy, and conization results in cervical dysplasia.HPV、传统巴氏涂片、阴道镜检查和宫颈锥切术在宫颈发育不良中的一致性。
Diagn Cytopathol. 2021 Jan;49(1):132-139. doi: 10.1002/dc.24655. Epub 2020 Oct 29.

引用本文的文献

1
Improving quality of care for cancer patients through oncological second opinions in a Comprehensive Cancer Center: adherence to second-opinion therapy recommendations.在综合癌症中心通过肿瘤学二次诊疗意见提高癌症患者的护理质量:对二次诊疗意见治疗建议的依从性。
J Cancer Res Clin Oncol. 2025 Apr 2;151(4):130. doi: 10.1007/s00432-025-06149-2.
2
Evaluation of endocervical curettage (ECC) in colposcopy for detecting cervical intraepithelial lesions.阴道镜检查中宫颈管刮术(ECC)用于检测宫颈上皮内病变的评估
Arch Gynecol Obstet. 2024 Dec;310(6):3037-3045. doi: 10.1007/s00404-024-07721-w. Epub 2024 Oct 29.
3
Implementation of quality indicators for vulvar cancer in gynaecological cancer centres certified by the German Cancer Society (DKG).

本文引用的文献

1
Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities.子宫颈癌的诊断、治疗与随访。德国妇科与产科学会、德国癌症协会和德国妇科与产科学会指南(S3级,德国医学科学与医学质量评估委员会登记号032/033OL,2021年5月) - 第2部分:关于心理肿瘤学、康复、随访、复发、姑息治疗和医疗设施的建议
Geburtshilfe Frauenheilkd. 2022 Feb 11;82(2):181-205. doi: 10.1055/a-1671-2446. eCollection 2022 Feb.
2
Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy.子宫颈癌的诊断、治疗与随访。德国妇科与产科学会(DGGG)、德国妇科肿瘤学会(DKG)和德国妇科与产科学会健康保险分会(DKH)指南(S3级,德国医学科学院质量与效率医学研究所登记号:032/033OL,2021年5月)——第1部分:关于流行病学、筛查、诊断与治疗的建议
Geburtshilfe Frauenheilkd. 2022 Feb 11;82(2):139-180. doi: 10.1055/a-1671-2158. eCollection 2022 Feb.
德国癌症学会(DKG)认证的妇科癌症中心外阴癌质量指标的实施。
J Cancer Res Clin Oncol. 2024 May 10;150(5):250. doi: 10.1007/s00432-024-05769-4.
4
Impact of the Corona Pandemic on Cervical Cancer Screening Assessment.新冠疫情对宫颈癌筛查评估的影响。
In Vivo. 2024 Mar-Apr;38(2):734-740. doi: 10.21873/invivo.13495.
5
Improving the Quality of Care for Cancer Patients through Oncological Second Opinions in a Comprehensive Cancer Center: Feasibility of Patient-Initiated Second Opinions through a Health-Insurance Service Point.通过综合癌症中心的肿瘤学二次诊疗意见提高癌症患者的护理质量:通过健康保险服务点由患者发起二次诊疗意见的可行性
Diagnostics (Basel). 2023 Oct 25;13(21):3300. doi: 10.3390/diagnostics13213300.
6
Cytology and HPV Co-Testing for Detection of Vaginal Intraepithelial Neoplasia: A Retrospective Study.细胞学与HPV联合检测用于阴道上皮内瘤变的检测:一项回顾性研究
Cancers (Basel). 2023 Sep 19;15(18):4633. doi: 10.3390/cancers15184633.
3
Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance.评估整合型人乳头瘤病毒DNA作为个体化生物标志物用于治疗后监测中复发性CIN2/3的检测
Cancers (Basel). 2021 Jul 1;13(13):3309. doi: 10.3390/cancers13133309.
4
Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix.子宫颈癌前病变或恶性病变女性中人乳头瘤病毒基因型分布
Arch Gynecol Obstet. 2021 Sep;304(3):751-758. doi: 10.1007/s00404-021-05986-z. Epub 2021 Feb 4.
5
Concordance rate of vulvoscopic findings in detecting early vulvar neoplasia.外阴镜检查在发现早期外阴肿瘤中的符合率。
Gynecol Oncol. 2020 May;157(2):463-468. doi: 10.1016/j.ygyno.2020.02.026. Epub 2020 Feb 24.
6
Accuracy of colposcopic findings in detecting vaginal intraepithelial neoplasia: a retrospective study.阴道上皮内瘤变的阴道镜检查准确性:一项回顾性研究。
Arch Gynecol Obstet. 2020 Mar;301(3):769-777. doi: 10.1007/s00404-020-05441-5. Epub 2020 Jan 28.
7
Correlation between referral cytology and in-house colposcopy-guided cytology for detecting early cervical neoplasia.转诊细胞学与阴道镜引导下细胞学检查在早期宫颈癌检测中的相关性。
Arch Gynecol Obstet. 2020 Jan;301(1):263-271. doi: 10.1007/s00404-019-05389-1. Epub 2019 Dec 6.
8
Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018).阴道癌及其前驱病变的诊断、治疗与随访。德国妇科与产科学会(DGGG)和德国妇科肿瘤学会(DKG)指南(S2k级别,德国医学科学信息平台[AWMF]登记号:032/042,2018年10月)
Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1060-1078. doi: 10.1055/a-0919-4959. Epub 2019 Jul 16.
9
Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 2 on Triage, Treatment and Follow-up.宫颈癌的预防:德国妇产科学会(DGGG)和德国妇科肿瘤学会(DKG)指南(S3级别,德国医学质量与效率理事会(AWMF)注册号015/027OL,2017年12月)——关于分流、治疗及随访的第2部分
Geburtshilfe Frauenheilkd. 2019 Feb;79(2):160-176. doi: 10.1055/a-0828-7722. Epub 2019 Feb 18.
10
Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 1 with Introduction, Screening and the Pathology of Cervical Dysplasia.宫颈癌的预防:德国妇产科学会和德国妇科肿瘤学会指南(S3级别,德国医学科学与医学质量评估研究所登记号015/027OL,2017年12月)——第1部分,包括引言、筛查及宫颈发育异常的病理学
Geburtshilfe Frauenheilkd. 2019 Feb;79(2):148-159. doi: 10.1055/a-0818-5440. Epub 2019 Feb 18.